Trial Profile
A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Therapeutic Use
- Acronyms PROTECT-1
- Sponsors Sandoz
- 07 Jun 2016 Results of a pooled analysis from PROTECT1 and PROTECT2 trials (n=624) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 12 Dec 2015 Primary endpoint has been met. (Duration of symptoms), as per an abstract presented at the 38th Annual San Antonio Breast Cancer Symposium
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium